406 related articles for article (PubMed ID: 20660056)
21. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
Takeshita A; Inoshita N; Taguchi M; Okuda C; Fukuhara N; Oyama K; Ohashi K; Sano T; Takeuchi Y; Yamada S
Eur J Endocrinol; 2009 Oct; 161(4):553-9. PubMed ID: 19589911
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
[TBL] [Abstract][Full Text] [Related]
24. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
[TBL] [Abstract][Full Text] [Related]
25. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
[TBL] [Abstract][Full Text] [Related]
26. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
[TBL] [Abstract][Full Text] [Related]
27. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
[TBL] [Abstract][Full Text] [Related]
28. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
30. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
31. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.
Jiang XB; Hu B; He DS; Mao ZG; Wang X; Song BB; Zhu YH; Wang HJ
BMC Cancer; 2015 Sep; 15():644. PubMed ID: 26400193
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
[TBL] [Abstract][Full Text] [Related]
34. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
[TBL] [Abstract][Full Text] [Related]
35. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
Salehi F; Scheithauer BW; Moyes VJ; Drake WM; Syro LV; Manoranjan B; Sharma S; Horvath E; Kovacs K
Endocr Pathol; 2010 Dec; 21(4):227-9. PubMed ID: 21061089
[TBL] [Abstract][Full Text] [Related]
36. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
[TBL] [Abstract][Full Text] [Related]
37. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
[TBL] [Abstract][Full Text] [Related]
38. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.
Walter T; van Brakel B; Vercherat C; Hervieu V; Forestier J; Chayvialle JA; Molin Y; Lombard-Bohas C; Joly MO; Scoazec JY
Br J Cancer; 2015 Feb; 112(3):523-31. PubMed ID: 25584486
[TBL] [Abstract][Full Text] [Related]
39. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
40. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]